SEC Form S-8 POS filed by LakeShore Biopharma Co. Ltd

$LSB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $LSB alert in real time by email
S-8 POS 1 ea0234439-s8pos_lakeshore.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

As filed with the U.S. Securities and Exchange Commission on March 14, 2025

Registration No. 333-279544

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-279544

 

UNDER

THE SECURITIES ACT OF 1933

 

 

 

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

 

 

 

Cayman Islands   Not Applicable
(State or other jurisdiction of
Incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

 

Cogency Global Inc.

122 East 42nd Street, 18th Floor

New York, NY 10168

+1 800-221-0102

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Rachel Yu

Chief Financial Officer

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing

People’s Republic of China

Telephone: 010-89202086

Will H. Cai, Esq.

Cooley LLP

c/o 35th Floor

Two Exchange Square

8 Connaught Place

Central, Hong Kong

+852 3758-1200

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer
Non-accelerated filer ☒ Smaller reporting company
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Post-Effective Amendment to Form S-8 (the “Post-Effective Amendment”) amends the Registration Statement on Form S-8 (File No. 333-279544) of LakeShore Biopharma Co., Ltd (the “Registrant”) filed with the Securities and Exchange Commission (the “Commission”) on May 20, 2024 (the “Registration Statement”), with respect to the ordinary shares, par value US$0.0002 per share, of the Registrant issuable pursuant to the Amended 2024 Plan (defined below).

 

Pursuant to section 3.1 of the Registrant’s 2024 Share Incentive Plan (the “Original 2024 Plan”), the maximum aggregate number of ordinary shares, par value US$0.00002 per share, of the Registrant (the “Shares”) which may be issued pursuant to all awards under the Original 2024 Plan (the “2024 Award Pool”) shall initially be 5,713,064 Shares, plus an annual increase on the first day of each fiscal year of the Registrant during the term of the Original 2024 Plan commencing with the fiscal year beginning on April 1, 2025, by (i) an amount equal to 1% of the total number of Shares issued and outstanding on the last day of the immediately preceding fiscal year, or (ii) such lesser number of Shares as may be determined by the Registrant’s board of directors (the “Evergreen Provision”). In March 2025, the Registrant’s board of directors approved to amend the Original 2024 Plan, for purposes of reflecting the share consolidation effective on October 1, 2024, and the early utilization of the Shares reserved for issuance under the Original 2024 Plan pursuant to the Evergreen Provision. Under the currently effective Amended 2024 Share Incentive Plan (the “Amend 2024 Plan”), the 2024 Award Pool was adjusted to 2,479,385 ordinary shares, par value US$0.0002 per share. The remainder of the Amended 2024 Plan remains the same as the Original 2024 Plan.

 

As a result, the Registrant is filing this Post-Effective Amendment to incorporate the Amended 2024 Plan as an exhibit to the Registration Statement and to reflect that a total of up to 2,479,385 ordinary shares have or will become available for issuance under the Amended 2024 Plan. The Registrant will file a new registration statement on Form S-8 to register additional ordinary shares authorized for issuance under the Amended 2024 Plan in the future where appropriate.

 

1

 

 

EXHIBITS

 

Exhibit No.   Description
99.1   Lakeshore Biopharma Co., Ltd Amended 2024 Share Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Form 6-K (File No. 001-41598) filed with the Commission on March 12, 2025)
24.1*   Powers of Attorney (included on signature page hereto)

 

*Filed herewith.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Beijing, China, on March 14, 2025.

 

  LakeShore Biopharma Co., Ltd
   
  By: /s/ Rachel Yu
  Name: Rachel Yu
  Title: Director and Chief Financial Officer  

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, severally and not jointly, Rachel Yu, with full power to act alone, as her or his true and lawful attorney-in-fact, with the power of substitution, for and in such person’s name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities on March 14, 2025.

 

Signature   Title
     
/s/ Dave Chenn    
Dave Chenn   Director and Chairperson of the Board
     
/s/ Hui Shao   Director, Vice Chairman of the Board and
Hui Shao   Chief Business Officer
     
/s/ Rachel Yu    
Rachel Yu   Director and Chief Financial Officer
     
/s/ Xu Wang    
Xu Wang   Chief Executive Officer and Director
     
/s/ Thomas Xue    
Thomas Xue   Director
     
/s/ Adam Zhao    
Adam Zhao   Director
     
/s/ Chunyang Shao    
Chunyang Shao   Director

 

3

 

 

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

 

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of LakeShore Biopharma Co., Ltd has signed this registration statement or amendment thereto in New York, New York on March 14, 2025.

 

  Authorized U.S. Representative
Cogency Global Inc.
     
  By: /s/ Colleen A. De Vries
  Name: Colleen A. De Vries
  Title: Senior Vice-President

 

 

4

 

Get the next $LSB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LSB

DatePrice TargetRatingAnalyst
More analyst ratings

$LSB
Press Releases

Fastest customizable press release news feed in the world

See more
  • LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

    Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoYAchieved gross profit of RMB 307.3 million, a growth of 39.1% YoYGross margin increased to 82.6% from 80.9% in the same period of FY2024Total operating expenses decreased to RMB 276.4 million, down 31.6% YoYRecorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024BEIJING, Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deli

    $LSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

    BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the "Bureau") has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang ("Former Chairman"). Investigation Details: The Company has uncovered evidence suggesting that Yi Zhang, during his tenure in key executive roles, misappropriated corporate assets for personal gain and mismana

    $LSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

    GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global leader in the discovery, development, manufacturing, and delivery of next-generation vaccines and therapeutic biologics for infectious diseases and cancer, today announced the initiation of its Biologics License Application (BLA) submission to the Drug Regulatory Authority of Pakistan (DRAP) for the conditional approval of its PIKA rabies vaccine for post-exposure prophylaxis. This submission is based on the results that met the primary endpoints of the vaccine's global pivotal trial and demonstrated the vaccine's potential to achieve accelerated

    $LSB
    $YS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LSB
SEC Filings

See more

$LSB
Leadership Updates

Live Leadership Updates

See more
  • LakeShore Biopharma Announces Leadership Transitions

    GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the board of directors of the Company (the "Board") has appointed Mr. Xu Wang as the Chief Executive Officer of the Company. He succeeds Mr. Dave Chenn and Dr. Hui Shao, who step down from the Company's Interim Chief Executive Officer and Co-Chief Executive Officer position, respectively. Mr. Xu Wang has served as the Company's Chief Operation Office

    $LSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LSB
Financials

Live finance-specific insights

See more
  • LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

    Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoYAchieved gross profit of RMB 307.3 million, a growth of 39.1% YoYGross margin increased to 82.6% from 80.9% in the same period of FY2024Total operating expenses decreased to RMB 276.4 million, down 31.6% YoYRecorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024BEIJING, Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deli

    $LSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

    GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on September 27, 2024 (Beijing Time) virtually via a Zoom video conference call. The EGM was called as part of the Company's efforts to regain compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1).

    $LSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

    GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m., Beijing time, on September 27, 2024, virtually via a Zoom video conference call, for the purpose of considering and, if thought fit, passing the proposed resolutions set forth in the notice of EGM (the "Notice of EGM"). Instructions for accessing the video confe

    $LSB
    Biotechnology: Pharmaceutical Preparations
    Health Care